A Three-Arm Randomized Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines

Owing to the increased number of patients treated with anthracycline-based adjuvant chemotherapy, there is a need for new effective and tolerable nonanthracycline regimens in metastatic breast cancer. Patients with HER2-negative metastatic breast cancer previously treated with anthracyclines in (neo)adjuvant setting were randomized to fully oral 3 weekly cycles of the combination of oral vinorelbine with capecitabine (V+C), to the same drugs alternating every three cycles (VC), or to the combination of docetaxel and capecitabine (D+C). V was given at 80mg/m2 (after the first cycle at 60mg/m2) on days 1 and 8 in the V+C arm and weekly in the VC arm, C at 1,000mg/m2 bid from days 1 to 14, and D on day 1 at 75mg/m2. The primary end point was disease control rate (CR+PR+NC3months). A total of 139 patients were randomly assigned to V+C (44 patients), VC (47 patients), and D+C (48 patients). After an independent review, the disease control rate in the intent-to-treat population in the V+C, VC, and D+C arms [95% CI] was 70.5% [54.883.2], 37.0% [23.252.5], and 70.8% [55.983.1], and the median overall survival 22.2, 19.4, and 24.2months, respectively. When taken into account the disease control rate, the alternating VC regimen seems to be less effective compared with V+C or D+C combinations. Combinations of V+C or D+C showed similar efficacy and a different toxicity profile; V+C induced less neutropenia, infection, hand-foot syndrome, fatigue/asthenia, and alopecia, whereas D+C less gastrointestinal toxicity. V+C combination constitutes a valuable fully oral alternative option to D+C in patients with metastatic breast cancer previously treated with anthracyclines in (neo)adjuvant setting, while offering the advantages of an all-oral treatment.